Pharmaceutical Services for Innovative Drugs

1.CDMO business of new drug Intermediates (Lab Grams-kg R & D Sample Supply, Process Optimization, cGMP & nGMP Scale-up Production)

2. Entrusted development of innovative drug CMC (including salt form and crystal form), non-clinical studies, assistance in pre-IND meeting application until IND license is obtained

3.Phase I, phase II clinical services for innovative drugs

4.Entrusted development services for Category 2 innovative drugs.

Nanjing Vcare provides from the supply of critical intermediates to CMC studies (including crystal form, salt form studies, drug substance synthesis, dosage form and strength confirmation), non-clinical studies, assists in pre-IND, meeting application and registration dossier submission until IND license is obtained, and can continue to serve the development of clinical phase I-II studies, and the whole lifecycle process of new drugs.

We have more than a decade of experience in the R&D of new drugs. The self-developed new drug Vicagrel has completed the pivotal clinical trials in China and the US, moreover, the phase I clinical trials of VC004 and VC005 also have been completed and the phase II clinical trials are underway. At the same time, we have successfully initiated many innovative drug projects and, after confirming the molecular structure of the compounds, promoted the project to IND filing in 12-14 months through cooperation with well-known domestic pharmaceutical companies and scientific research institutes. The projects cover multiple dosage forms (e.g., solid preparation, creams, inhalants, eye drops, oral solutions, gels), and involve the treatment of diseases (e.g., cardiovascular and cerebrovascular diseases, cancer, autoimmune disease, infection, digestive endocrine diseases) by acting on disease-related targets (e.g., P2Y12, ER-PROTAC, JAK, TRK, FLT3, Akt, PD-L1, and IL-17).